IMNM
Price:
$20.09
Market Cap:
$1.84B
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Industry
Biotechnology
IPO Date
2020-10-02
Stock Exchange
NASDAQ
Ticker
IMNM
According to Immunome, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.70B. This represents a change of 208.75% compared to the average of 551.45M of the last 4 quarters.
The mean historical Enterprise Value of Immunome, Inc. over the last ten years is 122.17M. The current 1.70B Enterprise Value has changed 139.26% with respect to the historical average. Over the past ten years (40 quarters), IMNM's Enterprise Value was at its highest in in the September 2024 quarter at 727.35M. The Enterprise Value was at its lowest in in the March 2024 quarter at -40168729.53.
Average
122.17M
Median
75.28M
Minimum
6.77M
Maximum
484.23M
Discovering the peaks and valleys of Immunome, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.60%
Maximum Annual Enterprise Value = 484.23M
Minimum Annual Increase = -93.27%
Minimum Annual Enterprise Value = 6.77M
| Year | Enterprise Value | Change |
|---|---|---|
| 2024 | 484.23M | 319.98% |
| 2023 | 115.30M | 1.60% |
| 2022 | 6.77M | -93.27% |
| 2021 | 100.63M | 71.35% |
| 2020 | 58.73M | -21.99% |
| 2019 | 75.28M | 427.66% |
The current Enterprise Value of Immunome, Inc. (IMNM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
202.10M
5-year avg
153.13M
10-year avg
122.17M
Immunome, Inc.’s Enterprise Value is greater than Pharvaris N.V. (1.34B), less than Spyre Therapeutics, Inc. (1.96B), greater than Intellia Therapeutics, Inc. (925.20M), greater than Upstream Bio, Inc. (1.46B), greater than Biohaven Ltd. (1.14B), less than Maze Therapeutics, Inc. (1.76B), less than Vera Therapeutics, Inc. (2.75B), greater than AbCellera Biologics Inc. (1.15B), less than Celldex Therapeutics, Inc. (1.95B), greater than Zenas BioPharma, Inc. (1.55B),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 1.34B | $1.80B | |
| 1.96B | $2.02B | |
| 925.20M | $1.02B | |
| 1.46B | $1.50B | |
| 1.14B | $1.02B | |
| 1.76B | $2.05B | |
| 2.75B | $2.72B | |
| 1.15B | $1.09B | |
| 1.95B | $1.97B | |
| 1.55B | $1.60B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immunome, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Immunome, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Immunome, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Immunome, Inc. (IMNM)?
What is the 3-year average Enterprise Value for Immunome, Inc. (IMNM)?
What is the 5-year average Enterprise Value for Immunome, Inc. (IMNM)?
How does the current Enterprise Value for Immunome, Inc. (IMNM) compare to its historical average?